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Abstract
Background
Viscoelastic near-patient assays of global hemostasis have been found useful and cost-
effective in perioperative settings. Shortcomings of current systems include substantial labo-
ratory intensity, user-dependent reproducibility, relatively large sample volumes, sensitivity
to ambient vibration and limited comparability between techniques and devices. The aim of
this study was to assess feasibility of a new, resonance-based viscoelastic whole blood
methodology (TEG6s) in cardiac surgery with cardiopulmonary bypass (CPB) and to com-
pare the parameters this system produces with the ROTEM delta system and standard
coagulation tests.
Methods
In a prospective evaluation study, twenty-three consecutive cardiac surgery patients under-
went hemostasis management according to current guidelines, using the ROTEM delta sys-
tem and standard coagulation tests. Blood samples were collected prior to CPB before
anesthetic induction (pre-CPB), during CPB on rewarming (CPB), and 10 minutes after hep-
arin reversal with protamine (post-CPB). ROTEM and standard coagulation test results
were compared with TEG6s parameters, which were concurrently determined using its
multi-channel microfluidic cartridge system.
Results
TEG6s provided quantifiable results pre-CPB and post-CPB, but only R (clotting time) of
CKH (kaolin with heparinase) was measurable during CPB (full heparinization). Spearman’s
correlation coefficient (rs) was 0.78 for fibrinogen levels and MA CFF (functional fibrinogen).
Correlation of several TEG6s parameters was good (0.77 to 0.91) with MCF FIBTEM, and
poor (<0.56) with prothrombin time and activated partial thromboplastin time (<0.44). Rs
with platelet count was moderate (0.70, MA CK; 0.73, MA CRT). Accuracy of MA CFF for
detection of fibrinogen deficiency < 1.5 g/L was high (ROC-AUC 0.93).
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Conclusions
The TEG6s system, which is based on resonance viscoelastic methodology, appears to be
feasible for POC hemostasis assessment in cardiac surgery. Its correlations with standard
coagulation parameters are quite similar to those of ROTEM and there is good diagnostic
accuracy for fibrinogen levels lower than 1.5 g/L. During full heparinization, TEG6s testing is
limited to R measurement. Larger studies are needed to assess superiority over other POC
systems.
Introduction
Cardiac surgery with cardiopulmonary bypass (CPB) is frequently complicated by coagulo-
pathic bleeding, which may require transfusion of allogenic blood products and may thus
worsen outcome. [1] Current guidelines recommend monitoring of hemostasis using visco-
elastic hemostatic assays (VHA) in conjunction with coagulation management algorithms,
with the aim to reduce patients‘transfusion exposure. [2–4] Point-of-care (POC) coagulation
monitoring with VHA is increasingly used to guide administration of factor concentrates,
especially in response to severe perioperative bleeding in cardiac surgery. [5–7]
Compared to standard laboratory coagulation testing, VHA provides comprehensive in
vitro evaluation of patients’ functional hemostasis rapidly enough to guide emergency treat-
ment. [8,9] During and after CPB, graphically displayed VHA results allow intuitive interpre-
tation and proposal of specific interventions (fibrinogen supplementation, additional
protamine administration) to improve coagulation rapidly. [10–13]
Established VHA instruments such as thromboelastography (TEG, Haemonetics Inc.,
Braintree, MA, USA) or thromboelastometry (ROTEM TEM International GmbH, Munich,
Germany) assess hemostasis properties by measuring shear forces between a pin and a blood-
filled cup. Oscillation is either generated by the pin or by the cup. [14] However, current VHA
are associated with important limitations—in particular, limited consistency. [10,15,16] These
systems are also bulky and sensitive to vibration. In addition, due to manual sampling and
mixing, skilled technicians are needed to perform frequent calibration and cleaning proce-
dures. [17]
To overcome these limitations, next-generation viscoelastic devices have been developed.
Haemonetics recently introduced a fully automated thromboelastograph, the TEG6s (Haemo-
netics Inc., Braintree, MA, USA).[18] The instrument assesses whole blood coagulation prop-
erties using the resonance method, which means that a blood sample within a four-channel
self-contained microfluidics cartridge is exposed to a sinusoidal motion range (20–500 Hz). As
clotting proceeds, clot-strength-specific resonance frequencies are detected by a photodetector
and converted into TEG-equivalent units. The latter are used to generate TEG tracings, which
are illustrating the viscoelastic change of the blood sample in real time. [18]
A faster test setup, which is portable, easy to maintain and does not require manual pipett-
ing and mixing would seem to be a promising innovation, allowing efficient POC coagulation
monitoring in patients undergoing cardiac surgery. [19] Considering these advantages, TEG6s
is aiming to replace established VHA systems. However clinical experience with TEG6s is lim-
ited and randomized, controlled evaluations are rare.
The aim of this study was to assess the feasibility of the TEG6s system in cardiothoracic sur-
gery. We studied the distribution of TEG6s results in the course of surgery, calculated
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reference ranges, determined the correlation between TEG6s results and established laboratory
parameters including thromboelastometry (ROTEM delta), and calculated the accuracy with
regard to fibrinogen deficiency.
Methods
Study design, setting and patients
This prospective observational study was conducted between July 11 and August 12, 2016, at a
tertiary care hospital. We included twenty-three consecutive adult patients scheduled for elec-
tive cardiovascular surgery with CPB. We observed the TEG6s measurements in the course of
cardiac surgery and explored associations between TEG6s measurements and established labo-
ratory parameters. Exclusion criteria were emergency surgery, age less than 18 years or absence
of informed consent. The study was approved by the Cantonal Ethics Committee (#18–00415)
and all patients gave their written informed consent. The manuscript adheres to reporting
guidelines on diagnostic accuracy (STARD).
Collection of data
Baseline characteristics of the patients (age, sex, body mass index, presence of concomitant dis-
orders, and treatment with anticoagulants or antiaggregants) were collected using the elec-
tronic patient record and transferred to a pseudonymized, encrypted database. Details of the
perioperative management were transferred from the anesthesia protocol, which included type
and details of surgery, and treatment with anticoagulants, coagulation factor concentrates and
allogeneic blood products. Laboratory tests were performed at three specified time points—
prior to CPB before anesthetic induction (pre-CPB), during CPB on rewarming (CPB) and 10
minutes after heparin reversal with protamine (post-CPB)—and transferred to the database
mentioned above.
Perioperative management of anesthesia, CPB technique, and hemostasis
All patients received general anesthesia. CPB was performed with two different systems, both
without heparin-coated components. For coronary artery bypass grafting (CABG) the mini-
mized extracorporeal circulation (MiECC, Maquet, Rastatt, Germany) was used. A conventional
extracorporeal circulation (CECC, Maquet) was used for all non-CABG cardiothoracic surger-
ies. Prior to aortic cannulation an initial bolus of heparin was administered (CECC: 500 IU/kg
ideal body weight (IBW); MiECC: 400 IU/kg IBW). Additional boluses of heparin were admin-
istered to maintain a target kaolin-activated clotting time (ACT, Activated Coagulation Timer
ACT II, Medtronic Minneapolis, USA) of> 480 seconds with MiECC and> 600 seconds with
CECC. Following CPB weaning, anticoagulation was antagonized with protamine chloride in a
1:1 ratio to the initial heparin bolus, targeting a normal post-interventional ACT value. Moder-
ate hypothermia was applied in all cases except for patients with hypothermic cardiocirculatory
arrest (HCA, 28 ˚C). Routinely all patients received a single bolus of tranexamic acid (dose: 10
mg/kg IBW), followed by a continuous infusion (5 mg/kg IBW/h) until sternal closure. In
patients requiring CECC, shed blood was either filtered and directly conducted to the cardiot-
omy reservoir during CPB or underwent filtration and cell salvage (Autolog, Medtronic Inc.,
Minneapolis, MN, USA) after CPB. Remaining blood in the CPB circuit was either cell salvaged
and retransfused (in CECC) or directly reinfused before heparin neutralization (in MiECC).
Administration of blood products and hemostatic agents was followed by the in-house
patient blood management (PBM) protocol which is a transfusion algorithm based on existing
literature incorporating tests results obtained from point-of-care devices (e.g. ROTEM).
Point-of-care coagulation cardiothoracic surgery
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Fibrinogen concentrate has been administered in case of persistent non-surgical bleeding
(> 150–200 ml/hr) after weaning from CPB and heparin neutralization if at the same time a
hypofibrinogenemia was present in ROTEM (FIBTEM A10 < 10 mm) or in the conventional
test (Clauss fibrinogen < 1.5 g/l). The target range of plasma fibrinogen was FIBTEM
A10> 12 mm or Clauss fibrinogen 1.5–2.0 g/l according to the recent guidelines set by the
European Society of Anesthesiology. [2]
Collection and handling of samples
Citrated blood samples were drawn under standardized conditions using citrated plastic syrin-
ges (0.106 mol/L; Monovette, Sarstedt, Nuembrecht, Germany) at the above mentioned three
specified time points. An established and implemented protocol was followed ensuring ade-
quate preanalytic conditions; samples for coagulometric tests were centrifuged for 15 minutes
at 1500 g. The following tests were performed simultaneously within 30 minutes: TEG6s,
ROTEM delta, fibrinogen (Clauss method), prothrombin time (PT; Quick percent), activated
partial thromboplastin time (aPTT), as well as platelet count.
Determination of TEG6s results
A TEG6s was implemented (Haemonetics Inc., Braintree, MA, USA) and analyses were con-
ducted within 30 minutes according to the manufacturer’s instructions. [17] In contrast to pre-
vious devices, no handling of reagents was necessary. The cartridges contained all required
reagents in four microfluidic channels: kaolin in the CK-channel, kaolin and tissue factor in
the CRT-channel, kaolin and heparinase in the CKH-channel, as well as kaolin and abciximab
in the CFF-channel. A small amount of citrated whole blood (0.3 ml) was pipetted into the car-
tridge, the carriage was placed in the device, and determination of the assays was initiated
automatically. An optical detector measured the movements of a blood meniscus exposed to a
fixed vibration frequency range and results were transformed to the TEG readout. More details
are described elsewhere. [17] For the purpose of our study, we recorded the clotting time (R)
and maximum clot strength (MA).
Determination of ROTEM measurements and other laboratory tests
Platelet counts were determined using a Coulter Counter LH750 (Beckman-Coulter Inc.,
Nyon, Switzerland).
Plasma levels of fibrinogen were measured according to the Clauss method using Multifib-
ren U reagent (Siemens Healthcare Diagnostics, Marburg, Germany). [20] Prothrombin time
was determined using Dade Innovin (Siemens Healthcare Diagnostics, Marburg, Germany)
and aPTT was measured using Pathrombin SL (Siemens Healthcare Diagnostics, Marburg,
Germany). All analyses were run on a CS5100 coagulometer (Siemens Healthcare Diagnostics,
Marburg, Germany). Thromboelastometry analysis was performed on a ROTEM delta ana-
lyzer according to the manufacturer’s instructions (ROTEM delta; Tem International GmbH,
Munich, Germany) with multiple-test reagents. INTEM, EXTEM, FIBTEM, and HEPTEM
test were conducted in citrated whole blood following a including the 5-minute pre-heating
procedure.
Statistical analysis
The correlation of TEG6s parameters with established laboratory parameters was considered
as main analysis. We were aiming for a minimum correlation of 0.55, a power of 0.8, and an α
of 0.05 (two-tailed). Following an established formula, [21], 22 patients were estimated.
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Median and 5th to 95th percentiles or frequency and percentages were reported as appropri-
ate. Spearman’s rank correlation coefficient (rs) was used to describe associations between
TEG6s results and established laboratory parameters. Wilcoxon matched-pairs signed rank
test was used to test differences of TEG6s results between pre-CPB and post-CPB measure-
ments. A receiver-operating characteristics curve (ROC) was constructed and area under the
curve (AUC) was calculated to explore the accuracy of MA CFF and MA CKH for fibrinogen
deficiency. All analyses were performed using the Stata 13.1 statistics software package (Stata-
Corp. 2013. Stata Statistical Software: Release 13. College Station, TX, USA); Figures were cre-
ated using GraphPad Prism version 6.00 for Mac OS X (GraphPad Software, La Jolla, CA,
USA).
Results
Baseline characteristics
Among the 23 patients included, seven (30%) underwent composite graft implantation, five
(22%) received coronary artery bypass surgery, two (9%) valve surgery, four (17%) combined
surgery and five (22%) other procedures. Median age was 67 years and 5 patients were female
(22%). Eleven patients (48%) received neither autologous blood products (e.g., packed red
blood cells [PRBC], fresh frozen plasma [FFP] or platelet concentrate [PLT]) nor fibrinogen or
other factor concentrates during and after surgery.
Detailed baseline characteristics as well as surgical details are presented in Table 1.
Distribution of TEG6 parameters in the course of surgery
Median and 5th to 95th percentiles (corresponding to reference ranges) of TEG6s parameters
in the course of surgery are reported in Table 2; their distribution is shown in Fig 1. Results in
the measurable range were observed pre-CPB and post-CPB for most patients and parameters
and for CPB in the case of R CKH. However, no results were determinable during CPB (full
heparinization) for MA CK, MA CRT, MA CFF, or R CK (partly determinable for MA CKH
and R CRT). Consequently, determination of functional fibrinogen during CPB using the
TEG6s’s CFF assay was not possible in our population. In addition, TEG6s on-pump ACT
measurements (CRT Channel, R time) showed a wide distribution, with 5th and 95th percentile
values of 958 seconds and 7347 seconds, respectively (Table 2), making reliable heparin moni-
toring using the TEG6s device during CPB unlikely.
Correlation of TEG6 results with established laboratory parameters
Correlation of TEG6s results with fibrinogen levels varied between 0.68 (MA CKH) and 0.80
(MA CK; MA CRT). Correlation was higher with regard to MCF FIBTEM (ROTEM; func-
tional fibrinogen), 0.77 in the case of MA CK, and 0.91 in the case of MA CFF. Lower correla-
tion coefficient were observed with regard to PT, aPTT and platelet count. Details are given in
Table 3, and scatter plots are illustrated in S1, S2 and S3 Figs.
Accuracy of TEG6 results with regard to hypofibrinogenemia
The area under the receiver-operating characteristics curve for the detection of fibrinogen lev-
els below 1.5 g/L was 0.93 in the case of MA CFF and 0.79 in the case of MA CKH. Thresholds
of 17.2 mm for MA CFF and of 57.3 mm for MA CKH yielded the best sensitivity and specific-
ity (Fig 2).
Point-of-care coagulation cardiothoracic surgery
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Discussion
The TEG6s was rapidly implemented for perioperative management in cardiothoracic surgery
and could be handled reliably without extensive training measures. Whereas interpretable
results were obtained in most patients in the pre-CPB and post-CPB period, few parameters
could be measured during full heparinization (R CKH). TEG6s parameters correlated ade-
quately with fibrinogen and functional fibrinogen (MCF FIBTEM) and the accuracy of MA
CFF for detecting fibrinogen levels below 1.5 g/L was high.
Table 1. Baseline characteristics.
Age, years 67 (26/78)
Female sex 5 (22)
BMI, kg/m2 25 (15/38)
Concomitant disorders:
Hypertension 15 (65)
COPD 4 (17)
Diabetes mellitus 1 (4)
CKD 10 (43)
Pre-operative treatment with antithrombotic drugs:
Antiaggregant drugs 15 (65)
Anticoagulants 5 (22)
Surgical procedure:
CABG 5 (22)
Valve surgery 2 (9)
Valve surgery and CABG 4 (17)
Thoracic aorta repair 2 (9)
Composite Graft 7 (30)
LVAD 1 (4)
Conduit 1 (4)
David procedure 1 (4)
Details of procedure
Procedural time, min 286 (204/508)
CPB, min 135 (52/214)
HCA 8 (35)
Anticoagulants, coagulation factors, and blood products:
Heparin, kU 40 (22/80)
Protamine, kU 40 (25/120)
PRBC, U 0 (0/8)
FFP, U 0 (0/5)
PLT, U 0 (0/2)
Autologous blood, ml 480 (0/1340)
Application of hemostatic agents:
Fibrinogen concentrate 9 (39)
Data correspond to median (minimum/ maximum) or number (percent), where appropriate. Pre-operative
anticoagulants were given less than five days prior to intervention. Abbreviations: BMI, body mass index; COPD,
chronic obstructive pulmonary disease; CKD, chronic kidney disease, def. as serum creatinine > 150 mmol/l; CABG,
coronary arterial bypass grafting; LVAD, left ventricular assist device; CPB, cardiopulmonary bypass; HCA,
hypothermic cardiocirculatory arrest; PRBC, packed red blood cell concentrates; FFP, fresh frozen plasma; PLT,
platelet concentrate; U, units; kU, kilo units
https://doi.org/10.1371/journal.pone.0209360.t001
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Table 2. Distribution of TEG6s parameters in the course of cardiothoracic surgery (reference ranges).
Parameter Pre-CPB CPB Post-CPB Probability+
Median
(5th, 95th percentile)�
Not clottable
(number, percent)
Median
(5th, 95th percentile)�
Not clottable
(number, percent)
Median
(5th, 95th percentile)�
Not clottable
(number, percent)
MA CK (mm) 58.9 (50.2, 67.4) 1 (4.3%) N/A 23 (100%) 51.2 (20.0, 66.9) 3 (13.0%) p = 0.003
R CK (min) 6.7 (5.8, 8.6) 1 (4.3%) N/A 23 (100%) 9.5 (7.1, 21.4) 1 (4.4%) p<0.0001
MA CRT (mm) 62.5 (51.2, 73.7) 1 (4.3%) 30.2 (2.5, 60.2) 19 (82.6%) 54.0 (44.1, 67.2) 0 p = 0.01
R CRT (min) 0.6 (0.4, 0.7) 1 (4.3%) 23 (9.7, 78.0) 13 (56.5%) 0.7 (0.4, 1.4) 0 p = 0.005
ACT CRT (sec) 102.0 (87.9, 116.0) 1 (4.3%) 2202.2 (957.9, 7347.0) 13 (56.5%) 116.0 (87.9, 181.5) 0 p = 0.006
MA CKH (mm) 59.9 (50.0, 67.4) 1 (4.3%) 55.8 (43.4, 65.2) 6 (26.1%) 54.6 (43.9, 65.2) 2 (8.7%) p = 0.01
R CKH (min) 6.5 (5.5, 8.2) 2 (8.7%) 12.1 (8.1, 17.5) 1 (4.3%) 9.4 (7.5, 13.2) 0 p<0.0001
MA CFF (mm) 21.6 (14.8, 48.6) 1 (4.3%) 2.6 (2.5, 2.7) 21 (91.3%) 18.0 (11.9, 28.3) 0 p = 0.09
Abbreviations: R = reaction time, MA = maximum amplitude, ACT = activated clotting time equivalent, CK = Kaolin TEG, CRT = rapid TEG, CKH = TEG with
heparinase, CFF = TEG functional fibrinogen, pre-CPB = values before cardiopulmonary bypass, CPB = during cardiopulmonary bypass, post-CPB = after
cardiopulmonary bypass;
� corresponding to reference ranges;
+ pre-CPB vs. post-CPB (Wilcoxon matched-pairs signed rank test)
https://doi.org/10.1371/journal.pone.0209360.t002
Fig 1. Pattern of TEG6s parameters in the course of cardiothoracic surgery. (A) reaction time (R), (B) maximum
amplitude (MA), and (C) activated clotting time equivalent (ACT) values are shown before cardiopulmonary bypass
(CPB; Pre), during (CPB) and after (Post). Abbreviations: CK, Kaolin TEG; CRT, rapid TEG; CKH, TEG with
heparinase; CFF, TEG functional fibrinogen.
https://doi.org/10.1371/journal.pone.0209360.g001
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Few previous studies have investigated the TEG6s device. Gurbel studied 300 patients
undergoing coronary revascularization in a first validation study in 2015. TEG6s measure-
ments demonstrated high precision as well as a strong correlation with the results of the estab-
lished TEG5000. In contrast to our study, those authors did not report any influence of
heparin administration on TEG6s parameters. [17] Moynihan investigated correlations
between heparin dose and alterations of TEG6s parameters (R times for CK and CKH) during
pediatric extracorporeal life support. Administering a smaller heparin dose (50 U/kg bolus, 20
Table 3. Correlation of TEG6s results with established coagulation parameters, platelet count, and thromboelastometry results.
TEG6s
parameters
Fibrinogen PT (Quick %) aPTT Platelet count MCF FIBTEM CT INTEM CT EXTEM MCF HEPTEM
Spearman’s rank correlation coefficient rs (95% CI)
R CK� 0.41 (0.10, 0.64) 0.39 (0.10,
0.62)
MA CK� 0.80 (0.65,
0.89)
-0.44 (-0.67,
-0.14)
0.70 (0.49,
0.84)
0.77 (0.60,
0.87)
R CRT� -0.56 (-0.74,
-0.31)
0.51 (0.25,
0.70)
MA CRT� 0.80 (0.65,
0.89)
0.48 (0.20, 0.68) 0.73 (0.55,
0.85)
0.85 (0.74,
0.92)
ACT CRT� 0.35 (0.04, 0.60)
MA CFF� 0.78 (0.63,
0.88)
0.91 (0.84,
0.95)
MA CKH+ 0.68 (0.30,
0.87)
0.83 (0.55,
0.94)
0.85 (0.58, 0.95)
Abbreviations: R = reaction time, MA = maximum amplitude, ACT = activated clotting time equivalent, CK = Kaolin TEG, CRT = rapid TEG, CKH = TEG with
heparinase, CFF = TEG functional fibrinogen,
� values before and after cardiopulmonary bypass were considered,
+ values during cardiopulmonary bypass were considered
https://doi.org/10.1371/journal.pone.0209360.t003
Fig 2. Accuracy of TEG6s results for hypofibrinogenemia (<1.5 g/L). ROC curves of (A) MA CFF and (B) MA CKH are shown.
(A) Area under the ROC curve (AUC) of MA CFF was 0.93 (95% CI 0.84, 1.00). At a threshold of 17.2 mm sensitivity was 100%
(95% CI 47.8, 100.0) and specificity 81.4% (95% CI 66.6, 91.7); (B) AUC of MA CKH 0.79 (95% CI 0.66, 0.93). At a threshold of 57.3
mm sensitivity was 100% (95% CI 71.5, 100.0) and specificity was 51% (95% CI 36.3, 65.6).
https://doi.org/10.1371/journal.pone.0209360.g002
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IU/kg/h maintenance targeting ACT of 300 sec) as in our study, Moynihan could measure fea-
sible values for TEG6s R time in the CK channel during CPB. [22] Furthermore, there has
been research into the influence of non-vitamin K oral anticoagulants (NOACs) or the effect
of sample storage duration on TEG6s parameters.
Comparability of these study results to our findings on CPB is limited, because blood sam-
ples in both studies were drawn from healthy blood donors without high dose heparinization.
[18,19] Finally, a recent study investigated TEG6s vibration resistance by placing it on a flatbed
platelet agitator. In contrast to their examination, we neither exposed our TEG6s device to
such vibration nor used blood samples from healthy donors. [23]
A strength of our study is that we looked at several important feasibility aspects of TEG6s in
the context of cardiothoracic surgery in clinical practice. We also had important limitations,
however. As a feasibility study, we had included a limited number of patients. Thus, the confi-
dence intervals are large and the estimations not very precise. We were also not able to associ-
ate the TEG6s measurements with clinical outcomes. Moreover, our results should be
confirmed in other settings as well. While TEG6s appears to be of limited value during CPB,
the high operator convenience and adequate correlation with fibrinogen levels (as well as func-
tional fibrinogen) suggests a potential improvement of perioperative hemostasis management.
Future studies including more patients must establish the benefit in different settings before
widespread implementation.
In conclusion, the new TEG6s device utilizing the resonance viscoelastic test system appears
to be an easy-to-use point-of-care device which may improve procedures in the perioperative
setting. Although correlation with established laboratory parameters is adequate, only a few
measurements could be performed during full heparinization. Larger studies would determine
the diagnostic accuracy in detail.
Supporting information
S1 Fig. Correlation of CFF and CKH parameters with conventional coagulation parame-
ters, platelet count as well as ROTEM results: Maximum amplitude (MA), maximum clot
firmness (MCF), CK, Kaolin TEG; CRT, rapid TEG; CKH, TEG with heparinase; CFF,
TEG functional fibrinogen. FIBTEM, Rotem with tissue factor and cytochalasin A; HEPTEM,
Rotem with partial thromboplastin phospholipid and heparinase.
(TIF)
S2 Fig. Correlation of CK, CKH, CRT, CFF parameters with conventional coagulation
parameters, as well as ROTEM results following cardiopulmonary bypass surgery: Maxi-
mum amplitude (MA), maximum clot firmness (MCF), CK, Kaolin TEG; CRT, rapid TEG;
CKH, TEG with heparinase; CFF, TEG functional fibrinogen. FIBTEM, Rotem with tissue
factor and cytochalasin A; HEPTEM, Rotem with partial thromboplastin phospholipid and
heparinase; INTEM, Rotem with partial thromboplastin phospholipid, EXTEM, Rotem with
tissue factor.
(TIF)
S3 Fig. Correlation of CK and CRT parameters with conventional coagulation parameters,
platelet count as well as ROTEM results following cardiopulmonary bypass surgery: Maxi-
mum amplitude (MA), maximum clot firmness (MCF), CK, Kaolin TEG; CRT, rapid TEG,
FIBTEM, Rotem with tissue factor and cytochalasin A.
(TIF)
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